SAGE Therapeutics (SAGE) Reports Q2 Loss of $0.36
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Stifel Transfers Sage Therapeutics (SAGE), Maintains Buy
August 6, 2018 4:16 PM EDTStifel assumes coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $239.00.
Analyst Paul Matteis assumes coverage, maintains Buy and raises the PT to $239.00 (from $198.00)
For an analyst ratings summary and ratings history on Sage Therapeutics... More
Piper Jaffray Starts Sage Therapeutics (SAGE ) at Overweight
August 6, 2018 5:34 AM EDTPiper Jaffray initiates coverage on Sage Therapeutics (NASDAQ: SAGE ) with a Overweight rating and a price target of $206.00.
Analyst Danielle Brill believes the company is attractive citing robust supportive data generated in 2018, the novel approach to threat of CNS disorders, the pipeline depth, and consistent management... More
